Quantum Leap Healthcare Collaborative

News & Announcements

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
I-SPY Email List Sign-up

I-SPY News

Press Release

August 6, 2019

I-SPY2 Presentations and Posters at SABCS 2018

Come see what I-SPY has been up to at the 2018 San Antonio Breast Cancer Symposium

News Update

November 22, 2018

Stream videos of I-SPY's September 12 Press Conference

Video available of the I-SPY press event held September 12, 2018.

News Update

October 25, 2018

Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer

Dynavax Technologies Corporation and Quantum Leap Healthcare Collaborative™ announced that Dynavax’s SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in the I-SPY 2 TRIAL

Press Release

October 15, 2018

News Update

September 14, 2018

Press Release

September 12, 2018

Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response

I-SPY investigators lauded for ‘mammoth task’ of imaging quality control in multicenter trials

News Update

September 7, 2018

Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab‎ For The I-SPY 2 Trial For Breast Cancer

A combination of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor olaparib and anti-PD-L1 monoclonal antibody immunotherapy agent durvalumab, both from AstraZeneca, will be evaluated in I-SPY 2.

Press Release

September 6, 2018